India to Russia: Bevacizumab Export Trade Route

The India to Russia Bevacizumab corridor is one of India's established pharmaceutical export routes, with 74 shipments documented worth a combined $23.6M USD. The route is dominated by DR.REDDY'S LABORATORIES LTD, which alone accounts for roughly 41% of all export value, reflecting the consolidated nature of India's bevacizumab manufacturing sector.

Across 6 active suppliers, the average shipment value stands at $318.9K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Sea freight dominates at 77% of all shipments, consistent with bevacizumab's non-urgent bulk-order profile.

Shipment activity peaks during July–September, with an average transit time of 27 days port-to-port. The route has recorded an annual growth rate of 30.0%, placing it at rank #18 among India's top bevacizumab export destinations globally.

On the import side, key buyers of Indian bevacizumab in Russia include JSC R-PHARM, JSC R-PHARM , JSC R PHARM and 3 others. JSC R-PHARM is the single largest importer with 29 shipments valued at $9.6M USD.

India's bevacizumab exports to Russia are driven primarily by a handful of large-scale manufacturers. DR.REDDY'S LABORATORIES LTD with 30 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 6 active exporters signals a competitive but concentrated market — buyers in Russia benefit from supplier diversity while the top tier handles the majority of volume.

The top 3 suppliers — DR.REDDY'S LABORATORIES LTD, DR.REDDY'S LABORATORIES LTD , DR REDDY S LABORATORIES LTD — together account for 99% of total trade value on this route. The average shipment value of $318.9K USD reflects primarily bulk commercial orders from large pharmaceutical distributors.

Beyond the primary product category, shipments on this route include closely related formulations such as bevacizumab wcb(working cell bank)(qty:3vials) and bevacizumab substance-frozen solution concentration 36.0 mg/ml with buffer solution 28,040 l(qty:1009.440 gms), suggesting that buyers in Russia tend to consolidate orders across related product lines from the same Indian supplier.

On the buying side, JSC R-PHARM is the largest importer with 29 shipments worth $9.6M USD — representing 41% of all bevacizumab imports from India on this route. A total of 6 buyers are active on this corridor.